Literature DB >> 26119047

Nitrogen-containing bisphosphonate therapy: assessment of the alveolar bone structure in rats - a blind randomized controlled trial.

Viviane N Pacheco1, Renan Langie1, Adriana Etges1, Deise Ponzoni1, Edela Puricelli1.   

Abstract

This study aimed to assess the effect of zoledronic acid exposure on structures of the alveolar bone of rats. The sample was composed of 42 male Wistar rats. Animals in the T1 and T2 groups received weekly doses of 0.2 mg/kg intraperitoneal zoledronic acid for 3 weeks, while animals in the T3 group received the same treatment for 8 weeks. The control groups C1, C2 and C3 received equivalent doses of saline. The first upper molars of Wistar rats in the C2, T2, C3 and T3 groups were extracted. Cone-beam computerized tomography scans were performed, and the image density was analysed by grey levels. The presence and type of inflammatory infiltrate, vascularization and bone necrosis were assigned by histological qualitative scores. Histomorphometric analysis of bone density was performed in the groups without extraction. No significant differences were found in the bone grey density estimated by grey-level value and histomorphometric analysis between the C1 and T1 groups (P > 0.05). The grey levels in the T3 group were lower (P < 0.05) than in the C3 group, corresponding to the bone defect. Histological assessments showed the presence of bone necrosis in the T3 group and lower levels of bone remodelling in the test groups (T2 and T3) compared to the control groups (C2 and C3). The results of qualitative analyses did not differ significantly between the groups (P > 0.05). Zoledronic acid-exposed animals showed maxillary changes including reduced grey levels, the presence of bone necrosis and a higher prevalence of inflammatory signs.
© 2015 The Authors. International Journal of Experimental Pathology © 2015 International Journal of Experimental Pathology.

Entities:  

Keywords:  bisphosphonate-associated osteonecrosis of the jaw; bone; bone density conservation agents; zoledronic acid

Mesh:

Substances:

Year:  2015        PMID: 26119047      PMCID: PMC4561562          DOI: 10.1111/iep.12133

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  19 in total

1.  Three-dimensional cephalometry: spiral multi-slice vs cone-beam computed tomography.

Authors:  Gwen R J Swennen; Filip Schutyser
Journal:  Am J Orthod Dentofacial Orthop       Date:  2006-09       Impact factor: 2.650

Review 2.  Mechanisms of action of bisphosphonates.

Authors:  G A Rodan
Journal:  Annu Rev Pharmacol Toxicol       Date:  1998       Impact factor: 13.820

Review 3.  Molecular mechanisms of action of bisphosphonates: current status.

Authors:  Anke J Roelofs; Keith Thompson; Sharon Gordon; Michael J Rogers
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

4.  Osteonecrosis of the jaws associated with the use of bisphosphonates. Discussion over 52 cases.

Authors:  H A Almăşan; Mihaela Băciuţ; H Rotaru; S Bran; Oana Cristina Almăşan; G Băciuţ
Journal:  Rom J Morphol Embryol       Date:  2011       Impact factor: 1.033

5.  Clinical comparison of patients with osteonecrosis of the jaws, with and without a history of bisphosphonates administration.

Authors:  M Kos; D Brusco; J Kuebler; W Engelke
Journal:  Int J Oral Maxillofac Surg       Date:  2010-11       Impact factor: 2.789

6.  Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.

Authors:  Robert E Marx; Yoh Sawatari; Michel Fortin; Vishtasb Broumand
Journal:  J Oral Maxillofac Surg       Date:  2005-11       Impact factor: 1.895

7.  Experimental development of bisphosphonate-related osteonecrosis of the jaws in rodents.

Authors:  Nicolau Conte Neto; Luis C Spolidorio; Cleverton R Andrade; Alliny S Bastos; Morgana Guimarães; Elcio Marcantonio
Journal:  Int J Exp Pathol       Date:  2013-02       Impact factor: 1.925

Review 8.  Bisphosphonates: a review of their pharmacokinetic properties.

Authors:  J H Lin
Journal:  Bone       Date:  1996-02       Impact factor: 4.398

9.  Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.

Authors:  Robert E Marx; Joseph E Cillo; Juan J Ulloa
Journal:  J Oral Maxillofac Surg       Date:  2007-12       Impact factor: 1.895

10.  Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.

Authors:  Salvatore L Ruggiero; Bhoomi Mehrotra; Tracey J Rosenberg; Stephen L Engroff
Journal:  J Oral Maxillofac Surg       Date:  2004-05       Impact factor: 1.895

View more
  6 in total

1.  The Severity of Interstitial Inflammation in the Renal Parenchyma of Albino Rats Is Subjected to the Dose of Heavy Metals.

Authors:  Hira Kareem; Amna Jahan; Rajia Liaqat; Tahira Liaqat; Sobia Jahangir; Hamza Shahab
Journal:  Cureus       Date:  2022-05-24

2.  Nitrogen-containing bisphosphonate therapy-Part II: Assessment of alveolar bone tissue inflammatory response in rats-A blind randomized controlled trial.

Authors:  Viviane N Pacheco; Renan Langie; Jules R D Benfica; Jéssica C Munaretto; Adriana Etges; Deise Ponzoni; Edela Puricelli
Journal:  Int J Exp Pathol       Date:  2018-11-20       Impact factor: 1.925

3.  Bone mineralization and vascularization in bisphosphonate-related osteonecrosis of the jaw: an experimental study in the rat.

Authors:  Jean-Daniel Kün-Darbois; Hélène Libouban; Guillaume Mabilleau; Florence Pascaretti-Grizon; Daniel Chappard
Journal:  Clin Oral Investig       Date:  2018-02-16       Impact factor: 3.573

Review 4.  Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  J I Aguirre; E J Castillo; D B Kimmel
Journal:  Bone       Date:  2021-09-11       Impact factor: 4.398

5.  Dental extraction following zoledronate, induces osteonecrosis in rat's jaw.

Authors:  X Vidal-Gutiérrez; J-F Gómez-Clavel; L-A Gaitán-Cepeda
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2017-03-01

6.  Beta tricalcium phosphate, either alone or in combination with antimicrobial photodynamic therapy or doxycycline, prevents medication-related osteonecrosis of the jaw.

Authors:  Henrique Hadad; Laís Kawamata de Jesus; Ana Flávia Piquera Santos; Henrique Rinaldi Matheus; Letícia Gabriella de Souza Rodrigues; Pier Paolo Poli; Elcio Marcantonio Junior; Fernando Pozzi Semeghini Guastaldi; Carlo Maiorana; Juliano Milanezi de Almeida; Roberta Okamoto; Francisley Ávila Souza
Journal:  Sci Rep       Date:  2022-10-03       Impact factor: 4.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.